# Schrodinger, Inc.: financial statements, quarterly

SDGR · Nasdaq · CIK 1490978 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sdgr.md) · [Financials](/companies/sdgr/financials.md) · [Filings](/companies/sdgr/filings.md) · [Insiders](/companies/sdgr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sdgr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [42.6](/filings/0001490978-24-000089.md) | [74.1 d](/filings/0001490978-26-000010.md) | [36.6](/filings/0001490978-25-000059.md) | [47.3](/filings/0001490978-25-000100.md) | [35.3](/filings/0001490978-25-000117.md) | [88.3 d](/filings/0001490978-26-000010.md) | [59.6](/filings/0001490978-26-000037.md) | [54.8](/filings/0001490978-26-000068.md) | [54.3](/filings/0001490978-25-000117.md) | [87.2 d](/filings/0001490978-26-000010.md) | [58.6](/filings/0001490978-26-000037.md) | [58.9](/filings/0001490978-26-000068.md) |
| Cost of revenue | $m | [18.9](/filings/0001490978-24-000089.md) | [16.6 d](/filings/0001490978-26-000010.md) | [17.7](/filings/0001490978-25-000059.md) | [16.0](/filings/0001490978-25-000100.md) | [17.6](/filings/0001490978-25-000117.md) | [24.2 d](/filings/0001490978-26-000010.md) | [28.4](/filings/0001490978-26-000037.md) | [28.6](/filings/0001490978-26-000068.md) | [26.3](/filings/0001490978-25-000117.md) | [29.9 d](/filings/0001490978-26-000010.md) | [29.0](/filings/0001490978-26-000037.md) | [26.5](/filings/0001490978-26-000068.md) |
| Gross profit | $m | [23.6](/filings/0001490978-24-000089.md) | [57.6 d](/filings/0001490978-26-000010.md) | [18.9](/filings/0001490978-25-000059.md) | [31.3](/filings/0001490978-25-000100.md) | [17.7](/filings/0001490978-25-000117.md) | [64.1 d](/filings/0001490978-26-000010.md) | [31.1](/filings/0001490978-26-000037.md) | [26.2](/filings/0001490978-26-000068.md) | [28.0](/filings/0001490978-25-000117.md) | [57.3 d](/filings/0001490978-26-000010.md) | [29.5](/filings/0001490978-26-000037.md) | [32.4](/filings/0001490978-26-000068.md) |
| Research and development | $m | [46.8](/filings/0001490978-24-000089.md) | [51.5 d](/filings/0001490978-26-000010.md) | [50.6](/filings/0001490978-25-000059.md) | [50.8](/filings/0001490978-25-000100.md) | [51.0](/filings/0001490978-25-000117.md) | [49.4 d](/filings/0001490978-26-000010.md) | [45.8](/filings/0001490978-26-000037.md) | [43.1](/filings/0001490978-26-000068.md) | [42.8](/filings/0001490978-25-000117.md) | [41.4 d](/filings/0001490978-26-000010.md) | [43.8](/filings/0001490978-26-000037.md) | [41.0](/filings/0001490978-26-000068.md) |
| Operating income | $m | [(56.2)](/filings/0001490978-24-000089.md) | [(29.6) d](/filings/0001490978-26-000010.md) | [(67.4)](/filings/0001490978-25-000059.md) | [(52.7)](/filings/0001490978-25-000100.md) | [(68.4)](/filings/0001490978-25-000117.md) | [(20.7) d](/filings/0001490978-26-000010.md) | [(50.9)](/filings/0001490978-26-000037.md) | [(52.9)](/filings/0001490978-26-000068.md) | [(45.9)](/filings/0001490978-25-000117.md) | [(17.2) d](/filings/0001490978-26-000010.md) | [(48.8)](/filings/0001490978-26-000037.md) | [(41.5)](/filings/0001490978-26-000068.md) |
| Income tax | $m | [(2.9)](/filings/0001490978-24-000089.md) | [(0.8) d](/filings/0001490978-26-000010.md) | [0.5](/filings/0001490978-25-000059.md) | [0.1](/filings/0001490978-25-000100.md) | [(0.1)](/filings/0001490978-25-000117.md) | [1.0 d](/filings/0001490978-26-000010.md) | [0.0](/filings/0001490978-26-000037.md) | [0.3](/filings/0001490978-26-000068.md) | [0.2](/filings/0001490978-25-000117.md) | [0.5 d](/filings/0001490978-26-000010.md) | [0.4](/filings/0001490978-26-000037.md) | [1.4](/filings/0001490978-26-000068.md) |
| Net income | $m | [(62.0)](/filings/0001490978-24-000089.md) | [(30.7) d](/filings/0001490978-26-000010.md) | [(54.7)](/filings/0001490978-25-000059.md) | [(54.0)](/filings/0001490978-25-000100.md) | [(38.1)](/filings/0001490978-25-000117.md) | [(40.2) d](/filings/0001490978-26-000010.md) | [(59.8)](/filings/0001490978-26-000037.md) | [(43.2)](/filings/0001490978-26-000068.md) | [(32.8)](/filings/0001490978-25-000117.md) | [32.5 d](/filings/0001490978-26-000010.md) | [(60.0)](/filings/0001490978-26-000037.md) | [6.0](/filings/0001490978-26-000068.md) |
| Diluted EPS | $ per share | [(0.86)](/filings/0001490978-24-000089.md) | not reported | [(0.76)](/filings/0001490978-25-000059.md) | [(0.74)](/filings/0001490978-25-000100.md) | [(0.52)](/filings/0001490978-25-000117.md) | not reported | [(0.82)](/filings/0001490978-26-000037.md) | [(0.59)](/filings/0001490978-26-000068.md) | [(0.45)](/filings/0001490978-25-000117.md) | not reported | [(0.81)](/filings/0001490978-26-000037.md) | [0.08](/filings/0001490978-26-000068.md) |
| Basic EPS | $ per share | [(0.86)](/filings/0001490978-24-000089.md) | not reported | [(0.76)](/filings/0001490978-25-000059.md) | [(0.74)](/filings/0001490978-25-000100.md) | [(0.52)](/filings/0001490978-25-000117.md) | not reported | [(0.82)](/filings/0001490978-26-000037.md) | [(0.59)](/filings/0001490978-26-000068.md) | [(0.45)](/filings/0001490978-25-000117.md) | not reported | [(0.81)](/filings/0001490978-26-000037.md) | [0.08](/filings/0001490978-26-000068.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [249](/filings/0001490978-23-000109.md) | [155](/filings/0001490978-25-000014.md) | [130](/filings/0001490978-24-000046.md) | [108](/filings/0001490978-24-000072.md) | [160](/filings/0001490978-24-000089.md) | [147](/filings/0001490978-26-000010.md) | [326](/filings/0001490978-25-000059.md) | [220](/filings/0001490978-25-000100.md) | [172](/filings/0001490978-25-000117.md) | [231](/filings/0001490978-26-000068.md) | [260](/filings/0001490978-26-000037.md) | [288](/filings/0001490978-26-000068.md) |
| Current assets | $m | [548](/filings/0001490978-23-000109.md) | [568](/filings/0001490978-25-000014.md) | [494](/filings/0001490978-24-000046.md) | [449](/filings/0001490978-24-000072.md) | [456](/filings/0001490978-24-000089.md) | [635](/filings/0001490978-26-000010.md) | [571](/filings/0001490978-25-000059.md) | [514](/filings/0001490978-25-000100.md) | [472](/filings/0001490978-25-000117.md) | [519](/filings/0001490978-26-000068.md) | [464](/filings/0001490978-26-000037.md) | [470](/filings/0001490978-26-000068.md) |
| Total assets | $m | [794](/filings/0001490978-23-000109.md) | [803](/filings/0001490978-25-000014.md) | [738](/filings/0001490978-24-000046.md) | [688](/filings/0001490978-24-000072.md) | [669](/filings/0001490978-24-000089.md) | [823](/filings/0001490978-26-000010.md) | [743](/filings/0001490978-25-000059.md) | [688](/filings/0001490978-25-000100.md) | [654](/filings/0001490978-25-000117.md) | [726](/filings/0001490978-26-000068.md) | [634](/filings/0001490978-26-000037.md) | [640](/filings/0001490978-26-000068.md) |
| Current liabilities | $m | [105](/filings/0001490978-23-000109.md) | [134](/filings/0001490978-25-000014.md) | [107](/filings/0001490978-24-000046.md) | [99.8](/filings/0001490978-24-000072.md) | [111](/filings/0001490978-24-000089.md) | [192](/filings/0001490978-26-000010.md) | [165](/filings/0001490978-25-000059.md) | [156](/filings/0001490978-25-000100.md) | [145](/filings/0001490978-25-000117.md) | [189](/filings/0001490978-26-000068.md) | [170](/filings/0001490978-26-000037.md) | [174](/filings/0001490978-26-000068.md) |
| Total liabilities | $m | [231](/filings/0001490978-23-000109.md) | [254](/filings/0001490978-25-000014.md) | [224](/filings/0001490978-24-000046.md) | [214](/filings/0001490978-24-000072.md) | [220](/filings/0001490978-24-000089.md) | [402](/filings/0001490978-26-000010.md) | [370](/filings/0001490978-25-000059.md) | [345](/filings/0001490978-25-000100.md) | [332](/filings/0001490978-25-000117.md) | [362](/filings/0001490978-26-000068.md) | [321](/filings/0001490978-26-000037.md) | [311](/filings/0001490978-26-000068.md) |
| Shareholders' equity | $m | [564](/filings/0001490978-23-000109.md) | [549](/filings/0001490978-26-000010.md) | [514](/filings/0001490978-25-000117.md) | [474](/filings/0001490978-25-000117.md) | [449](/filings/0001490978-25-000117.md) | [421](/filings/0001490978-26-000068.md) | [374](/filings/0001490978-26-000068.md) | [343](/filings/0001490978-26-000068.md) | [321](/filings/0001490978-25-000117.md) | [364](/filings/0001490978-26-000068.md) | [314](/filings/0001490978-26-000068.md) | [329](/filings/0001490978-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(49.9) d](/filings/0001490978-24-000089.md) | [(37.3) d](/filings/0001490978-26-000010.md) | [(39.3)](/filings/0001490978-25-000059.md) | [(53.7) d](/filings/0001490978-25-000100.md) | [(33.3) d](/filings/0001490978-25-000117.md) | [(31.1) d](/filings/0001490978-26-000010.md) | [144](/filings/0001490978-26-000037.md) | [(52.2) d](/filings/0001490978-26-000068.md) | [(61.9) d](/filings/0001490978-25-000117.md) | [(16.1) d](/filings/0001490978-26-000010.md) | [(14.8)](/filings/0001490978-26-000037.md) | [(34.1) d](/filings/0001490978-26-000068.md) |
| Capital expenditure | $m | [4.9 d](/filings/0001490978-24-000089.md) | [2.5 d](/filings/0001490978-26-000010.md) | [4.1](/filings/0001490978-25-000059.md) | [1.0 d](/filings/0001490978-25-000100.md) | [1.3 d](/filings/0001490978-25-000117.md) | [0.9 d](/filings/0001490978-26-000010.md) | [0.6](/filings/0001490978-26-000037.md) | [0.3 d](/filings/0001490978-26-000068.md) | [0.5 d](/filings/0001490978-25-000117.md) | [0.0 d](/filings/0001490978-26-000010.md) | [2.5](/filings/0001490978-26-000037.md) | [0.4 d](/filings/0001490978-26-000068.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [71.2](/filings/0001490978-23-000109.md) | [73.8](/filings/0001490978-24-000046.md) | [75.1](/filings/0001490978-24-000072.md) | [71.9](/filings/0001490978-24-000089.md) | [72.3](/filings/0001490978-25-000059.md) | [72.7](/filings/0001490978-25-000100.md) | [72.8](/filings/0001490978-25-000117.md) | [73.1](/filings/0001490978-26-000037.md) | [73.4](/filings/0001490978-26-000068.md) | [73.6](/filings/0001490978-25-000117.md) | [74.0](/filings/0001490978-26-000037.md) | [75.8](/filings/0001490978-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.